Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0TYCAG
ADC Name
SC-004
Synonyms
SC-004
   Click to Show/Hide
Organization
Stemcentrx (Top20 MNC) (Originator)
Drug Status
Phase 1 (discontinued)
Drug-to-Antibody Ratio
2
Structure
Antibody Name
An antibody targeting CLDN6/9
  Antibody Info 
Antigen Name
Claudin-6 (CLDN6); Claudin-9 (CLDN9)
  Antigen Info 
Payload Name
SGD-1882
  Payload Info 
Therapeutic Target
Human deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Val-Cit linker
  Linker Info 
Conjugate Type
Reactive Cysteines
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
Indication Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 New Drug Application Approved
Fallopian tube cancer
1 Trials
Trial ID
NCT03138408
Ovarian cancer
1 Trials
Trial ID
NCT03138408
Peritoneal cancer
1 Trials
Trial ID
NCT03138408
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
progressive disease (PD)  NCT03138408
PHASE1
An Open Label, Phase 1 Study of SC-004 as Monotherapy and in Combination With ABBV-181 in Subjects With Epithelial Ovarian, Including Fallopian Tube and Primary Peritoneal and Endometrial Cancers
partial response (PR)  NCT03138408
PHASE1
An Open Label, Phase 1 Study of SC-004 as Monotherapy and in Combination With ABBV-181 in Subjects With Epithelial Ovarian, Including Fallopian Tube and Primary Peritoneal and Endometrial Cancers
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data progressive disease (PD)
21%
Patients Enrolled
Eligible patients must have platinum-resistant ovarian or endometrial cancer (≤3 prior lines), ECOG 0-1, adequate organ function, with exclusion for prior PBD/IND-based therapy.
Administration Dosage
.
Related Clinical Trial
NCT Number NCT03138408  Clinical Status PHASE1
Clinical Description An Open Label, Phase 1 Study of SC-004 as Monotherapy and in Combination With ABBV-181 in Subjects With Epithelial Ovarian, Including Fallopian Tube and Primary Peritoneal and Endometrial Cancers
Primary Endpoint
Safety evaluation includes DLT assessment (NCI CTCAE v4.03) during the first 21-day cycle and QTcF monitoring over 9 weeks.
Other Endpoint
PK parameters (Ctrough, Cmax, Tmax, T1/2, AUC) will be analyzed for 1 year; efficacy endpoints (ORR, CBR, PFS, OS, DOR, DOCB) will be tracked for 2 years.
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data partial response (PR)
5%
Patients Enrolled
Eligible patients must have platinum-resistant ovarian or endometrial cancer (≤3 prior lines), ECOG 0-1, adequate organ function, with exclusion for prior PBD/IND-based therapy.
Administration Dosage
.
Related Clinical Trial
NCT Number NCT03138408  Clinical Status PHASE1
Clinical Description An Open Label, Phase 1 Study of SC-004 as Monotherapy and in Combination With ABBV-181 in Subjects With Epithelial Ovarian, Including Fallopian Tube and Primary Peritoneal and Endometrial Cancers
Primary Endpoint
Safety evaluation includes DLT assessment (NCI CTCAE v4.03) during the first 21-day cycle and QTcF monitoring over 9 weeks.
Other Endpoint
PK parameters (Ctrough, Cmax, Tmax, T1/2, AUC) will be analyzed for 1 year; efficacy endpoints (ORR, CBR, PFS, OS, DOR, DOCB) will be tracked for 2 years.
References
Ref 1 SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers